Statute Details
- Title: Human Biomedical Research (Tissue Banking) Regulations 2019
- Act Code: HBRA2015-RG3
- Legislative Type: Subsidiary Legislation (SL)
- Authorising Act: Human Biomedical Research Act 2015 (Section 63)
- Commencement: 1 November 2019
- Current Version: 2025 Revised Edition (2 June 2025); status current as at 27 March 2026
- Parts: Part 1 (Preliminary); Part 2 (Tissue Banks Generally); Part 3 (Tissue for Human Tissue Transplantation Research); Part 4 (Miscellaneous)
- Key Provisions (as reflected in the extract): Section 2 (Definitions); Parts 2–4 including notifications, donor confidentiality, tracking, safety/welfare, incidental findings, documentation, contamination management, quality systems, electronic system, false information, and fees
- Key Schedules: First Schedule (Declaration of compliance); Second Schedule (Fees)
What Is This Legislation About?
The Human Biomedical Research (Tissue Banking) Regulations 2019 (“Tissue Banking Regulations”) are Singapore’s detailed regulatory rules for tissue banks that provide human tissue for biomedical research. They sit under the Human Biomedical Research Act 2015 (“HBRA”), translating the Act’s high-level framework into practical compliance obligations for tissue banking activities.
In plain terms, the Regulations require tissue banks and, in certain circumstances, recipients of tissue, to put in place governance and safety systems. These include advance notifications to the relevant authority, designation of a responsible person, documentation and traceability, donor confidentiality protections, and prompt reporting of serious adverse events and other untoward occurrences. The Regulations also address what must happen before tissue is removed, supplied, released, or exported, and how tissue contamination and quality management should be handled.
Although the Regulations are “tissue banking” focused, they also cover a specific research pathway: tissue for “human tissue transplantation research”. This is important because transplantation research carries heightened ethical and clinical risk. The Regulations therefore impose additional requirements on documentation, tracking, and quality/safety management for tissue used in that context.
What Are the Key Provisions?
1) Definitions that shape compliance duties. Section 2 is foundational. It defines terms that determine when the Regulations apply and what triggers reporting or procedural obligations. For example, “recipient” includes researchers and research institutions that receive tissue from a tissue bank, but excludes the individual to whose body the tissue is transplanted or grafted. This matters because the compliance burden for “recipient” obligations is aimed at the research side, not the clinical recipient patient.
The definition of “untoward occurrence” is particularly significant. It captures a broad range of events associated with the removal of human tissue primarily for research, including outcomes that affect patient safety and research integrity: death, life-threatening events, hospitalisation or prolonged hospitalisation, persistent disability, transmission of communicable disease, misidentification or mix-up of tissue/gametes/embryo, and congenital anomalies or birth defects. By defining “untoward occurrence” in this way, the Regulations ensure that reporting is not limited to obvious clinical harms; it also includes errors and mix-ups that could compromise safety and validity.
2) Governance and notifications for tissue banks. Part 2 sets out the operational compliance framework for tissue banks generally. It includes requirements for notification by the tissue bank (Part 2, including sections on notification of tissue banking activity and notifications under the HBRA). A tissue bank must designate a “principal person in charge” (section 6), which is the individual designated under section 35(2)(b) of the HBRA. Practically, this designation is a compliance anchor: regulators and auditors can identify who is accountable for ensuring that the bank’s systems meet statutory requirements.
Part 2 also addresses ongoing administrative duties: changes of information and particulars (section 7), and a declaration of compliance (section 8, supported by the First Schedule). Declarations of compliance are often used to formalise attestation that the tissue bank meets regulatory standards. For practitioners, these provisions are not merely paperwork—they can become central evidence in enforcement, licensing, or judicial review contexts.
3) Safety reporting: serious adverse events and untoward occurrences. The Regulations contain multiple notification provisions (sections 10–13) dealing with serious adverse events and untoward occurrences. The structure distinguishes between (a) notification by the tissue bank and (b) notifications under the HBRA that relate to serious adverse events and untoward occurrences arising from removal of tissue. This is a key compliance area because it requires timely communication to the authority and ensures that adverse events are tracked across the tissue supply chain.
Part 2 also includes notification of cessation of operations (section 14). This is important for risk management: when a tissue bank stops operating, there must be clarity about the status of tissue holdings, records, and any ongoing obligations to donors or recipients.
4) Pre-supply controls, confidentiality, and traceability. Section 15 sets out requirements before tissue is removed, supplied or exported. While the extract does not reproduce the full text of section 15, the heading indicates a “before you act” compliance model: tissue banks must satisfy specified conditions prior to removal, supply, or export. This typically includes consent-related checks, eligibility and safety screening, and ensuring that the tissue meets quality requirements.
Section 16 protects confidentiality of the donor’s information. In practice, this means tissue banks must handle donor data in a way that respects privacy and limits disclosure to authorised purposes. For lawyers, confidentiality provisions often interact with consent terms, data protection obligations, and disclosure rules during investigations or audits.
Section 17 requires tracking of consent and integrity of records. This is a traceability requirement: regulators expect tissue banks to be able to reconstruct what happened to tissue from donor consent through processing and onward supply. Record integrity is crucial for both safety investigations (e.g., identifying the source of contamination or mix-up) and for legal defensibility.
5) Donor welfare and incidental findings. Section 18 addresses safety and welfare of donors. This reflects the ethical premise that donors are not merely “sources” of tissue; their health and safety must be protected throughout removal and related processes. Section 19 requires a policy on incidental findings. Incidental findings are results discovered outside the primary research purpose—often raising complex questions about whether, how, and to whom such information should be communicated. A statutory requirement for a policy indicates that tissue banks must have a structured approach rather than ad hoc decisions.
6) Additional requirements for tissue used in transplantation research. Part 3 applies to “tissue for human tissue transplantation research” and contains additional layers of compliance. Section 21 requires documentation, while section 22 requires tracking of information relevant to safety and quality of tissue. These provisions reinforce that transplantation research requires higher assurance and more robust traceability.
Section 23 imposes additional requirements before tissue is released, supplied or exported in this transplantation research context. Section 24 requires notification by the recipient of human tissue, which is a notable shift: the recipient is not just a passive receiver. Section 25 addresses management of tissue contamination, and section 26 requires quality and safety management systems. Together, these provisions indicate that the regulatory model expects both the tissue bank and the recipient ecosystem to maintain systems capable of preventing, detecting, and responding to contamination and quality failures.
7) Operational and enforcement mechanics: electronic systems, false information, and fees. Part 4 includes section 27 on an electronic system, which likely governs how notifications and submissions are made (the definition of “relevant website” in section 2 points to https://elis.moh.gov.sg/tiaras). Section 28 prohibits false information, which is a standard enforcement hook: inaccurate submissions can trigger regulatory action. Section 29 provides for fees, supported by the Second Schedule. For practitioners, fee provisions matter for budgeting and for ensuring that applications/notifications are not delayed due to administrative non-compliance.
How Is This Legislation Structured?
The Regulations are organised into four parts:
Part 1 (Preliminary) contains citation and definitions (sections 1–2). This is where key terms such as “recipient” and “untoward occurrence” are defined.
Part 2 (Tissue Banks Generally) sets the baseline compliance obligations for tissue banks. It covers notification duties, designation of a principal person in charge, updates and declarations, adverse event/untoward occurrence reporting, cessation notifications, pre-removal/supply/export requirements, confidentiality, consent and record tracking, donor safety and welfare, and policies on incidental findings.
Part 3 (Tissue for Human Tissue Transplantation Research) adds heightened requirements for transplantation research. It focuses on documentation and tracking for safety and quality, additional pre-release/supply/export controls, recipient notification, contamination management, and quality and safety management systems.
Part 4 (Miscellaneous) provides administrative and enforcement-related provisions: use of an electronic system, prohibition on false information, and fees (including the Second Schedule).
Who Does This Legislation Apply To?
The Regulations primarily apply to tissue banks operating in Singapore that remove, store, process, supply, release, or export human tissue for biomedical research. The obligations in Part 2 apply broadly to tissue banks generally, including governance, notifications, confidentiality, tracking, and donor welfare requirements.
In addition, recipients—including researchers and research institutions—are within the scope of certain obligations, particularly under Part 3. Section 24’s notification requirement by the recipient indicates that recipients must participate in the regulatory reporting and traceability ecosystem. Notably, the definition of “recipient” excludes the individual to whose body the tissue is transplanted or grafted, meaning patient clinical care obligations are not framed as “recipient” duties under these Regulations.
Why Is This Legislation Important?
For practitioners advising tissue banks, research institutions, or compliance teams, these Regulations are important because they operationalise the HBRA’s ethical and safety objectives into enforceable duties. The Regulations create a compliance architecture that supports donor protection, research integrity, and public confidence in biomedical research supply chains.
From an enforcement perspective, the reporting provisions for serious adverse events and untoward occurrences are central. The breadth of the “untoward occurrence” definition—covering not only clinical harms but also misidentification and mix-ups—means that compliance failures can have regulatory consequences even where there is no immediate clinical deterioration. Lawyers should therefore treat traceability and record integrity (sections 17 and related provisions) as both a safety mechanism and a litigation/defence asset.
Practically, the Regulations also affect how organisations design their internal systems: governance structures (principal person in charge), documentation standards, consent tracking, confidentiality controls, contamination response plans, and quality management systems. The requirement for a policy on incidental findings (section 19) further means that tissue banks must address ethically sensitive scenarios in advance, with documented decision-making frameworks.
Related Legislation
- Human Biomedical Research Act 2015 (authorising Act; including provisions referenced such as section 35(2)(b), section 35(3), and section 63)
- Human Biomedical Research Act 2015 (section 27(3) referenced in the definition of “non-identifiable”)
Source Documents
This article provides an overview of the Human Biomedical Research (Tissue Banking) Regulations 2019 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.